Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics

To infinity and beyond: Strategies for fabricating medicines in outer space

“…The ability to transform microorganisms to serve as biofactories brings new options for manufacturing biological drugs ( El Karoui et al, 2019 ; Trosset and Carbonell, 2015 ). The creation of synthetic biology platforms capable of operating outside of well-controlled laboratory conditions could enable its deployment in areas with limited resources and variable storage conditions, such as remote military and space missions, for the on-demand production of protein-based drugs ( Bendicho-Lavilla et al, 2022 ; Brooks and Alper, 2021 ). Given how promising this discipline is, NASA’s Translational Research Institute for Space Health (TRISH) has funded a project at the Massachusetts Institute of Technology (MIT) to develop a gastric resident device for in-situ production of drugs, called the “mother machine”.…”

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis

“…The protective role of GLP-1R signaling in diabetic nephropathy is attributed to its hypoglycemic effect and anti-oxidative effect 24 , 25 , 26 , 27 , 28 . On the other hand, glucagon has been shown to improve mitochondrial turnover and function in various tissues, including the liver, heart, and muscle 29 , 30 .…”

Oral nano-formulation improves pancreatic islets dysfunction via lymphatic transport for antidiabetic treatment

“…Although various well-established treatments (insulin, sulfonylureas, α -glycosidase inhibitors, thiazolidinediones, etc.) have made great achievements in controlling blood glucose level, pancreatic islet β -cells and their circumstances are still in pathologic condition 3 , 8 , 9 , 10 . Therefore, improving pancreatic microenvironment to reverse islet β -cell dysfunction provides a promising strategy for anti-T2DM therapy.…”